19) Elevated levels of alanine aminotransferase and aspartate aminotransferase may suggest hepatic injury, but these elevations along with significantly elevated levels of creatine phosphokinase
, lactate dehydrogenase, and a high ratio of aspartate aminotransferase to alanine aminotransferase should indicate the correct diagnosis of rhabdomyolysis.
Isoenzymes of creatine phosphokinase
in tissue extracts and in normal and pathological sera.
Animals were killed after blood was taken for creatine phosphokinase
(CPK) measurement on the fourteenth day.
On day 16 after the patient was admitted to the hospital, results of laboratory testing showed improved values for creatine phosphokinase
(1,855 ng/mL), aspartate aminotransferase (101 IU/L), alanine aminotransferase (162 IU/L), lactate dehydrogenase (294 IU/L), and urine myoglobulin (10 [micro]g/L).
A rise in plasma creatine phosphokinase
concentration and myoglobinuria, without clinical sequelae, were noted post delivery.
The most common Grade 3/4 adverse events (AEs) reported in >2% of patients receiving treatment with the 200 mg dose were elevated levels of creatine phosphokinase
A recently identified statin-triggered, immune-mediated necrotizing myopathy needs to be considered among the possible explanations for statin-induced muscle symptoms and creatine phosphokinase
elevations that persist despite discontinuation of the lipid-lowering drug.
Hematochemistry showed high creatine phosphokinase
levels, leukocyte count 1,380 cell/[mm.
Significant differences between age groups were identified in glucose, potassium, phosphorus, calcium, albumin, total plasma protein, globulin, cholesterol, bile acid, and zinc concentrations, as well as aspartate aminotransferase, alkaline phosphatase, lactate dehydrogenase, and creatine phosphokinase
activities (P < .
Postresuscitation creatine phosphokinase
and creatine kinase-MB were 2,150 U/L (NR, 60-190 U/L) and 48 U/L (NR, 0-16 U/L), respectively.
Cardiac specific creatine phosphokinase
isoenzyme in the diagnosis acute myocardial infarction.
Patients receiving CUBICIN should be observed for the development of muscle pain or weakness and have creatine phosphokinase
(CPK) levels monitored weekly if unexplained symptoms develop.